Increased body mass index as a risk factor in localized prostate cancer treated by radical prostatectomy

Gbenou, Maximilien C. Goris; Peltier, Alexandre; Schulman, Claude; Velthoven, Roland Van

doi:10.1016/j.urolonc.2015.12.009

Cited by 8 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 28 ] who studied the relationship between obesity and blood pressure in Southeastern Nigeria and Goris-Gbenou et al . [ 29 ] who studied an American population. Furthermore, studies by Freedland et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation between body mass index and gleason score in men with prostate cancer in Southeastern Nigeria

et al. 2021

View full text Add to dashboard Cite

Introduction: Prostate cancer has an increasing global burden. The clinical course varies from an indolent disease to a rapidly aggressive cancer. It is associated with higher mortality in less developed nations due to late presentation. The Gleason scoring system for prostatic adenocarcinoma has prognostic implications in diagnosed cases. Obesity has been associated with the evolution of many cancers including prostate cancer. There are conflicting reports on the relationship between obesity, as measured by body mass index (BMI), and prostate cancer aggressiveness, as measured by Gleason score. This study is aimed to determine if a correlation exists between BMI and Gleason score in men with prostate cancer. Methodology: This was a prospective, hospital-based, cross-sectional study involving consecutive patients with prostate cancer. Clinical evaluation including anthropometry, digital rectal examination, and relevant investigations were done for each patient and data collected with pro forma. This was followed by prostate needle biopsy and those diagnosed with adenocarcinoma of the prostate had their Gleason grades and scores obtained. Data were analyzed statistically using Spearman Correlation. Results: The mean age of the patients was 69.54 ± 8.61 years (range 47–83 years). The BMI ranged from 16.98 to 36.45 kg/m 2 , with a mean of 27.03 ± 5.03 kg/m 2 . Twenty-six of the patients (36.1%) were overweight and 34.7% were obese. The mean total prostate-specific antigen was 118.65 ± 84.43 ng/ml, with a range of 31–406 ng/ml. The modal Gleason score was 9 with a range of 4–10. There was a strong positive correlation between BMI and Gleason score ( r = 0.817, P = 0.0003). Conclusion: The BMI of patients with prostate cancer correlated positively with their Gleason score.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[ 31 ] and a mean Gleason score of 5.87 ± 1.17 by Goris-Gbenou et al . [ 29 ] This could be due to early presentation of the patients used in those studies and thus, lesser tumor burden. Furthermore, it has been observed that men of African descent are more likely to have higher Gleason scores and present with more advanced disease.…”

Section: Discussionmentioning

confidence: 99%

Correlation between body mass index and gleason score in men with prostate cancer in Southeastern Nigeria

et al. 2021

View full text Add to dashboard Cite

show abstract

“…At present, the clinical indicators for the diagnosis of PCa are a PSA value ≥4 ng/ml and a positive digital rectal test ( 33 ). A previous study found that in patients undergoing a radical prostatectomy, a higher body mass index (BMI) was associated with a higher prostate weight and PSA, as well as higher pT staging and pathological Gleason score ( 34 ). A higher percentage of fatty tissue around the prostate has been shown to be significantly associated with a higher Gleason score ( 35 ).…”

Section: Pcamentioning

confidence: 99%

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Pan,

Tong,

Ren

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle-aged males between the ages of 45 and 60 years, and is the highest cause of cancer-associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N 6 -methyladenosine (m 6 A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m 6 A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m 6 A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m 6 A methylation modification in PCa. It is considered that the treatment of PCa with micro-molecular drugs that target the epigenetics of the m 6 A regulator to correct abnormal m 6 A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.

show abstract

A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials

Sultan

Ghebrezadik

Smith

et al. 2023

J. Racial and Ethnic Health Disparities

View full text Add to dashboard Cite

Increased body mass index as a risk factor in localized prostate cancer treated by radical prostatectomy

Cited by 8 publications

References 27 publications

Correlation between body mass index and gleason score in men with prostate cancer in Southeastern Nigeria

Correlation between body mass index and gleason score in men with prostate cancer in Southeastern Nigeria

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials

Contact Info

Product

Resources

About

Increased body mass index as a risk factor in localized prostate cancer treated by radical prostatectomy

Cited by 8 publications

References 27 publications

Correlation between body mass index and gleason score in men with prostate cancer in Southeastern Nigeria

Correlation between body mass index and gleason score in men with prostate cancer in Southeastern Nigeria

Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials

Contact Info

Product

Resources

About

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)